USPTO serial 79267807
KHERION
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 13, 2021
- Examiner
- KELLEY, EVELYN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with KHERION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John P. McCormick
John P. McCormick Fish & Richardson P.C.P.O. Box 1022Minneapolis, MN 55440UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, cardiovascular diseases or disorders, metabolic diseases or disorders, inflammation, cancer, and diabetes; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical, medical and veterinary preparations and substances for the treatment and prevention of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, cardiovascular diseases or disorders, metabolic diseases or disorders, inflammation, cancer, and diabetes; pharmaceutical, medical and veterinary preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases or disorders; enzymes for medical and veterinary purposes; vaccines; diagnostic agents, reagents, preparations and substances for pharmaceutical, medical and veterinary purposes; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, namely, blood fraction proteins; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases or disorders, namely, human plasma proteins; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, namely, animal plasma proteins; gene regulatory proteins for medical use; Biological preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, namely, antibodies; antibody receptors for medical use; antigens for medical use; antigen receptors for medical use; sanitary preparations for medical and veterinary purposes; preparations for destroying vermin; fungicides, herbicides; molecular components and complexes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders | ACTIVE | — |
| 009 | Electronic data in recorded form and downloadable electronic publications in the nature of reports, articles, e-books and e-zines relating to enzymes, vaccines, pharmaceuticals and pharmaceutical, medical and veterinary preparations and substances | ACTIVE | — |
| 042 | Scientific and technological services and research and design relating thereto relating to enzymes, vaccines, pharmaceuticals and pharmaceutical, medical and veterinary preparations and substances; research in the field of molecular biology; pharmaceutical, medical and veterinary research; industrial analysis in the biological, pharmaceutical, medical, and veterinary fields; industrial research services in the fields of pharmaceuticals, medicine and science; research, development, testing and evaluation of pharmaceuticals and of pharmaceutical, medical and veterinary preparations and substances; research, development, testing and evaluation of enzymes and of diagnostic agents, reagents, preparations and substances for pharmaceutical, medical and veterinary purposes; provision of information and consultancy in relation to any of the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kherion Technology Limited
- Other trademarks owned by Kherion Technology Limited
- Other trademarks owned by Kherion Technology Limited
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named KHERION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 13, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Nov 15, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 24, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 23, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 13, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 13, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 3, 2021 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Apr 27, 2021 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Apr 17, 2021 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Apr 17, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 13, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 24, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 24, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 12, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 24, 2020 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Nov 24, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 24, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 21, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 4, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 4, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 4, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 19, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 16, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 16, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 16, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 16, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 27, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 27, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 27, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 28, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 28, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 28, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 2, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 2, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 16, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 15, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 1, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 1, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 19, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |